Dr. Dino Dina

Dr. Dino Dina, M.D. served as the CEO of Dynavax Technologies Corporation from May 1998 to May 1, 2013. Dr. Dina has served as President of Dynavax Technologies Corporation since May 1997.

He joined Dynavax Technologies Corporation in 1997, Dr. Dina was an employee of Chiron Corporation, a biopharmaceutical company. At Chiron, Dr. Dina held a series of positions with increasing responsibility. He ultimately served as President at Chiron Vaccines (formerly Biocine Company), which he directed from its inception in 1987.

Under Dr. Dina’s direction, Chiron Vaccines received the first-ever approval for an adjuvanted influenza vaccine in Italy, successfully completed the development of the first genetically engineered pertussis vaccine, and conducted clinical trials for vaccines to prevent HIV, herpes simplex type II, cytomegalovirus and hepatitis B infections.

The virology group he directed was responsible for several key scientific findings, including the discovery, cloning and sequencing of the hepatitis C virus and the cloning and sequencing of the viral genomes for HIV and hepatitis A viruses. Prior to joining Chiron, Dr. Dina was employed at the Albert Einstein College of Medicine in Bronx, New York, as an assistant professor of genetics from 1977 to 1982.

He was a Director of Symphony Dynamo, Inc and was an Executive Director at Dynavax Technologies Corporation from May 1997 to October 2014. He received his M.D. from the University of Genova Medical School in Italy.